$VTEX

Gomide de Faria Mariano sold $19K of VTEX (indirect holdings)

Gomide de Faria Mariano (Chief Executive Officer) sold 4,808 indirectly-held shares of VTEX (VTEX) at $4.00 on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gomide de Faria Mariano
Published Jun 29, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTEX
Neutral
medium confidence
Mentioned
$VTEX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTEXNeutralLow
01

Why it matters

This adds a fresh datapoint on insider activity, but it does not include new guidance, contracts, litigation, or operational changes that would typically drive repricing.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure and small disclosed value limit actionable impact.

03

What to watch

The filing is indirect holdings and does not reveal whether other insiders or institutions are buying/selling; also the disclosed dollar amount is small relative to typical market impact.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-29 after-hours/late day SEC disclosure; reflects sale executed 2026-06-26.

Background

The article is an SEC Form 4 insider transaction disclosure for VTEX, reporting an open-market sale by the CEO via indirect holdings under a 10b5-1 plan.

Company-level read

Ticker impact

$VTEXNeutralMedium confidence
Context

VTEX disclosed an SEC Form 4 showing CEO Gomide de Faria Mariano sold 4,808 shares at $4.00 on 2026-06-26 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a scheduled open-market sale (10b5-1) with modest disclosed value ($19.2k) and no accompanying company-specific operational or financial update.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may be mechanically driven by liquidity/tax planning rather than bearish expectations.

Key entities

  • VTEX

    Issuer of the SEC Form 4 insider transaction disclosure.

  • Gomide de Faria Mariano

    VTEX CEO who sold 4,808 shares at $4.00/share on 2026-06-26 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTEXMed

VTEX (VTEX) Just Turned A Profit Corner, But Growth Is Slowing

VTEX (NYSE:VTEX) reported Q2 2026 results showing improved profitability with non-GAAP income from operations up 62.4% YoY to $13.8M, and free cash flow up 79.1% to $12.7M. However, revenue growth slowed to 1.3% YoY on an FX-neutral basis, with management expecting flat growth for Q3. The company repurchased 6.2M shares for $23.2M during the quarter.

$VTEXMedAI 8/10

VTEX (VTEX) Q2 2026 Earnings Call Transcript

VTEX reported Q2 2026 results in an earnings call. GMV was $5.7B, up 7% FX-neutral. Subscription revenue was $63.8M, up 1.3% FX-neutral. Non-GAAP operating income rose 62% to $13.8M, with a 21.4% margin. Free cash flow was $12.7M, up 79%. Q3 guidance calls for flat FX-neutral subscription growth.

$VTEXMedAI 8/10

VTEX Q2 Earnings Call Highlights

VTEX (NYSE:VTEX) reported Q2 margin and cash flow improvement and guided for Q3 and full-year low-single-digit FX-neutral subscription revenue growth and low-20% non-GAAP operating and free cash flow margins. Q2 non-GAAP subscription gross margin rose to 81.8%. Free cash flow rose 79% to $12.7M. VTEX repurchased 6.2M shares at $3.76.

$VTEXMed

VTEX (VTEX): Financial results for Q2 2026

VTEX (VTEX) furnished an SEC Form 6-K — earnings release. VTEX Reports Second Quarter 2026 Financial Results Subscription revenue grew 11.4% (+1.3% FXN), with GMV up 17.8% (+7.0% FXN) Non-GAAP income from operations increased 62.4% to US$13.8 million, reaching a 21.4% margin Free cash flow increased 79.1% to US$12.7 million, reaching a